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Generalized epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome characterized by the presence
of febrile and afebrile seizures. The first gene, GEFS1, was mapped to chromosome 19q and was identified as the
sodium-channel b1-subunit, SCN1B. A second locus on chromosome 2q, GEFS2, was recently identified as the
sodium-channel a1-subunit, SCN1A. Single-stranded conformation analysis (SSCA) of SCN1A was performed in
53 unrelated index cases to estimate the frequency of mutations in patients with GEFS+. No mutations were found
in 17 isolated cases of GEFS+. Three novel SCN1A mutations—D188V, V1353L, and I1656M—were found in 36
familial cases; of the remaining 33 families, 3 had mutations in SCN1B. On the basis of SSCA, the combined
frequency of SCN1A and SCN1B mutations in familial cases of GEFS+ was found to be 17%.
Introduction
Generalized epilepsy with febrile seizures plus (GEFS
[MIM 604236]) was first described by Scheffer and Ber-
kovic (1997) and is now recognized as a common epi-
lepsy syndrome (Baulac et al. 1999;Moulard et al. 1999;
Peiffer et al. 1999; Singh et al. 1999; Scheffer et al.
2000). Although GEFS is familial, it was initially dif-
ficult to recognize it as a distinct syndrome, because of
clinical heterogeneity within each family. The common
phenotypes are typical febrile seizures (FS) and febrile
seizures plus (FS); FS differs from FS in that the
attacks with fever continue beyond age 6 years and/or
include afebrile tonic-clonic seizures. Less common phe-
notypes include FS associated with absences, my-
oclonic or atonic seizures, and even more-severe syn-
dromes, such as myoclonic-astatic epilepsy. That such
phenotypic diversity could be associated with the seg-
regation of a mutation in a single gene was established
by the identification of a mutation in the voltage-gated
sodium-channel b1-subunit gene, SCN1B (Wallace et al.
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1998). This mutation, C121W, changes a conserved cys-
teine residue, disrupting a putative disulfide bridge,
which results in in vitro loss of function of the b1-sub-
unit. Without a functional b1-subunit, the rate of in-
activation of sodium-channel a-subunits decreases,
which may cause increased sodium influx and thereby
result in a more depolarized membrane potential and
hyperexcitability. Modifier genes or the environment
may interact with the SCN1B gene to account for clinical
heterogeneity, but the rarity of SCN1B mutations (Wal-
lace et al. 1998) strongly suggests that additional genes
of large effect underlie GEFS in other families (Singh
et al. 1999).
GEFS in four families has been mapped to chro-
mosome 2q (Baulac et al. 1999; Moulard et al. 1999;
Peiffer et al. 1999; Lopes-Cendes et al. 2000). Recently,
mutations in the neuronal voltage-gated sodium-chan-
nel a1-subunit gene, SCN1A, were described in two of
these families (Escayg et al. 2000). These mutations,
T875M and R1648H, are located in highly conserved
S4 transmembrane segments of the channel, which are
known to have a role in channel gating. It was suggested
that these mutations may reduce the rate of inactivation
of SCN1A and therefore may have an effect similar to
that of the b1-subunit mutation.
GEFS is clearly a common complex disorder, with
a strong genetic basis, incomplete penetrance, and ge-
netic and phenotypic heterogeneity. FS occur in 3% of
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the population, and thus this phenotype may occur spo-
radically in families with GEFS, in addition to oc-
curring as a result of the GEFS gene (Wallace et al.
1998). Also, although some families segregate an au-
tosomal dominant gene of major effect, in many cases
the clinical genetic evidence (such as bilineality) suggests
that in some small families the disorder is multifactorial
(Singh et al. 1999). Despite this evidence, large families
continue to be ascertained, and, with critical phenotypic
analysis, they provide opportunities to localize and, ul-
timately, identify the genes involved.
The present article describes the genomic organiza-
tion of SCN1A and the frequency of mutations in 53
unrelated patients with GEFS. Three novel SCN1A
mutations were identified, giving GEFS-associated
SCN1Amutations a frequency of 5.6%. Several SCN1A
polymorphisms are also identified, which may prove
useful in future association studies.
Subjects and Methods
Subjects
A group of 53 unrelated probands with GEFS phe-
notypes were studied. These subjects were ascertained
on the basis of twin and family studies and on the basis
of routine clinical practice. Phenotypes in probands and
family members were classified as described elsewhere
(Scheffer and Berkovic 1997; Singh et al. 1999). Familial
cases ( ) were those in which at least one first-np 36
degree relative of the proband had a phenotype within
the GEFS spectrum. Informed consent was obtained
from all subjects.
The Australian family in figure 1A, which has been
described extensively elsewhere (Scheffer and Berkovic
1997; Lopes-Cendes et al. 2000), is the original pedigree
leading to the initial delineation and description of the
GEFS syndrome. The Israeli family in figure 1B is of
Ashkenazi origin and spans six generations. Twelve fam-
ily members had seizures. In the two oldest members—
I-2 and III-3—seizures had occurred in childhood, but
the data were insufficient to allow classification of the
phenotype. Of the 10 other family members who had
seizures, 3 had FS with onset at age 9–13 mo and that
terminated by age 1–4 years, with 1–7 attacks each, and
five had FS with onset at age 9–24 mo and that ter-
minated at age 5–41 years, with 2–15 attacks each. Sei-
zures during childhood were a mixture of FS and afebrile
tonic-clonic seizures, whereas the rarely occurring sei-
zures during teenage and adult years were all afebrile.
Subject V-16 had a more severe phenotype, with ∼20
febrile seizures at age 6 mo–5 years, 10 afebrile tonic-
clonic seizures at age 5–15 years, and occasional com-
plex partial seizures associated with mild learning dif-
ficulties. She was classified as having FS and complex
partial seizures. Her older sister, V-15, had typical FS,
but their younger brother, V-17, had no FS but had two
afebrile tonic-clonic seizures at ages 12 years 6 mo and
14 years. For purposes of linkage analysis, he was re-
garded as affected, although he had only afebrile tonic-
clonic seizures. All affected subjects were of normal or
superior intellect, except V-16 (see above), and all had
a normal neurological examination. Electroencephalog-
raphy (EEG) studies had been performed infrequently
during the active phase of the epilepsy, and the results
usually either were normal or were reported as showing
generalized discharges.
The second Israeli family was of Druze origin; the par-
ents were from different but proximate villages and were
not known to be related. This family spans two genera-
tions, and four family members had seizures (fig. 1C). The
proband, I-2, age 41 years, had had hundreds of tonic-
clonic seizures, sometimes with fever. These began at age
4 years and continued, at a rate of approximately one per
month, until the time of the study. The proband was
mildly intellectually impaired. EEG showed generalized
irregular spike-wave and polyspike-wave discharges, and
FS was diagnosed. Of her four children, the oldest, II-
1, was unaffected, two, II-2 and II-4, had FS, and one,
II-3, had FS.
Isolation and Sequencing of SCN1A Genomic Clones
A human bacterial artificial chromosome (BAC) li-
brary from Genome Systems was screened by a PCR
product amplified with the primer pair 5′-AGATGA-
CCAGAGTGAATATGTGACTAC-3′ and 5′-CCAATG-
GTAAAATAATAATGGCGT-3′, designed from the par-
tial cDNA sequence of SCN1A (GenBank accession
number X65362). BAC 129e04 was selected for sub-
cloning and sequencing. BAC DNA was nebulized and
size fractionated on 0.8% agarose gels, and 2–4-kb frag-
ments were subcloned into pUC18 vector. This subli-
brary was used in shotgun sequencing to generate single
complete coverage of the BAC clone. Sequence data were
assembled in contigs, by Phred, Phrap, and Gap4 high-
throughput sequencing software. Exon-intron bounda-
ries were predicted on the basis of the rat Scn1a cDNA
sequence (GenBank accession numberM22253) because
the full-length human cDNA sequence was not known.
Single-Stranded Conformation Analyses (SSCA) and
Sequencing
HEX-labeled primers were designed to amplify all ex-
ons of SCN1A (table 1). A 30-ng sample of patient DNA
was amplified in a total volume of 10 ml. Products were
separated on nondenaturing 4% polyacrylamide gels
containing 2% glycerol, by the GelScan 2000 (Corbett
Research). PCR products showing a conformational
change were reamplified, by unlabeled primers from 100
ng of genomic DNA, and were sequenced by the BigDye
Terminator ready-reaction kit (PE Biosystems).
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Figure 1 GEFS pedigrees. DNA was not available from those individuals not assigned a letter (X, Y, or Z) or a 0. A, Australian family,
with numbering based on figure 1 in the article by Scheffer and Berkovic (1997). B, Ashkenazi family. C, Druze family.
Results
The 8,381-bp cDNA of SCN1A is organized into 27
exons spanning 1100 kb of genomic DNA. To facilitate
comparison with related sodium channels SCN4A,
SCN5A, and SCN8A, the first untranslated exon is des-
ignated “exon 1A,” and the second exon, containing the
start codon, remains “exon 1.” Two different splice-
donor sites were identified in exon 11, resulting in two
transcripts that differ by 11 amino acids in the first cy-
toplasmic loop. Intronic primers (table 1), designed to
amplify each of the 27 exons of SCN1A, were used to
screen for mutations in patients with GEFS.
A total of 53 unrelated patients with GEFS were
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Table 1
Primers Designed to Amplify All Exons of SCN1A
EXONa
PRIMER
(5′r3′)
SIZE
(bp)Forward Reverse
1A TACCATAGAGTGAGGCGAGG ATGGACTTCCTGCTCTGCCC 356
1 CCTCTAGCTCATGTTTCATGAC TGCAGTAGGCAATTAGCAGC 448
2 CTAATTAAGAAGAGATCCAGTGACAG GCTATAAAGTGCTTACAGATCATGTAC 356
3 CCCTGAATTTTGGCTAAGCTGCAG CTACATTAAGACACAGTTTCAAAATCC 263
4 GGGCTACGTTTCATTTGTATG GCAACCTATTCTTAAAGCATAAGACTG 355
5 AGGCTCTTTGTACCTACAGC CATGTAGGGTCCGTCTCATT 199
6 CACACGTGTTAAGTCTTCATAGT AGCCCCTCAAGTATTTATCCT 394
7 GAACCTGACCTTCCTGTTCTC GTTGGCTGTTATCTTCAGTTTC 241
8 GACTAGGCAATATCATAGCATAG CTTTCTACTATATTATCATCCGG 320
9 TTGAAAGTTGAAGCCACCAC CCACCTGCTCTTAGGTACTC 363
10 GCCATGCAAATACTTCAGCCC CACAACAGTGGTTGATTCAGTTG 480
11a TGAATGCTGAAATCTCCTTCTAC CTCAGGTTGCTGTTGCGTCTC 306
11b GATAACGAGAGCCGTAGAGAT TCTGTAGAAACACTGGCTGG 315
12 CATGAAATTCACTGTGTCACC CAGCTCTTGAATTAGACTGTC 347
13a ATCCTTGGGAGGTTTAGAGT CATCACAACCAGGTTGACAAC 292
13b CTGGGACTGTTCTCCATATTG GCATGAAGGATGGTTGAAAG 277
14 CATTGTGGGAAAATAGCATAAGC GCTATGCAGAACCCTGATTG 338
15a TGAGACGGTTAGGGCAGATC AGAAGTCATTCATGTGCCAGC 348
15b CTGCAAGATCGCCAGTGATTG ACATGTGCACAATGTGCAGG 276
16a GTGGTGTTTCCTTCTCATCAAG TCTGCTGTATGATTGGACATAC 387
16b CAACAGTCCTTCATTAGGAAAC ACCTTCCCACACCTATAGAATC 353
17 CTTGGCAGGCAACTTATTACC CAAGCTGCACTCCAAATGAAAG 232
18 TGGAAGCAGAGACACTTTATCTAC GTGCTGTATCACCTTTTCTTAATC 234
19 CCTATTCCAATGAAATGTCATATG CAAGCTACCTTGAACAGAGAC 318
20 CTACACATTGAATGATGATTCTGT GCTATATACAATACTTCAGGTTCT 216
21a ACCAGAGATTACTAGGGGAAT CCATCGAGCAGTCTCATTTCT 303
21b ACAACTGGTGACAGGTTTGAC CTGGGCTCATAAACTTGTACTAAC 297
22 ACTGTCTTGGTCCAAAATCTG TTCGATTAATTTTACCACCTGATC 267
23 AGCACCAGTGACATTTCCAAC GGCAGAGAAAACACTCCAAGG 272
24 GACACAGTTTTAACCAGTTTG TGTGAGACAAGCATGCAAGTT 207
25 CAGGGCCAATGACTACTTTGC CTGATTGCTGGGATGATCTTGAATC 477
26-1 CGCATGATTTCTTCACTGGTTGG GCGTAGATGAACATGACTAGG 247
26-2 TCCTGCGTTGTTTAACATCGG ATTCCAACAGATGGGTTCCCA 288
26-3 TGGAAGCTCAGTTAAGGGAGA AGCGCAGCTGCAAACTGAGAT 261
26-4 CCGATGCAACTCAGTTCATGGA GTAGTGATTGGCTGATAGGAG 274
26-5 AGAGCGATTCATGGCTTCCAATCC TGCCTTCTTGCTCATGTTTTTCCACA 335
26-6 CCTATGACCGGGTGACAAAGCC TGCTGACAAGGGGTCACTGTCT 242
a More than one PCR was required to amplify the large exons 11, 13, 15, 16, 21, and 26.
screened by fluorescent SSCA, including two families
consistent with mapping to the same location as SCN1A
on chromosome 2 (fig. 1A and B). No mutations were
found in the 17 sporadic cases of GEFS that were
tested. Of the 36 families tested, 3 were found to have
point mutations in SCN1A, which alter the amino acid
sequence and are not present in the control population
( ). The phenotype in the family in fig. 1A pre-np 60
viously had been mapped to chromosome 2 (Lopes-
Cendes et al. 2000) and carries a c.563ArT mutation
that segregates with affected family members. This mu-
tation in exon 4 of SCN1A results in a D188V amino
acid substitution that lies just outside the S3 segment
of domain I (fig. 2A). The aspartic acid residue is con-
served in all identified sodium channels in humans, as
well as in many different animal species—except the
jellyfish, which has an arginine at this residue, and the
flatworm, which has a serine (fig. 2B). (The published
rat Scn2a sequence [GenBank accession number
NM_012647] also has an arginine in place of the as-
partic acid, at residue 188.)
A mutation in exon 21 (c.4057GrC) of SCN1A was
found to segregate with GEFS in the Ashkenazi family
(fig. 1B). This mutation changes a highly conserved
amino acid (V1353L) located in the S5 segment of do-
main III (fig. 2). One family member, V-13, did not carry
the mutation (fig. 1B). This was determined by testing
the DNA of a parent of this family member, since the
subject’s DNA was unavailable. This individual, who
had FS that terminated at an early age, is likely to be
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Table 2
Sequence Variants of SCN1A Detected in 53 GEFS+ Samples and
in 60 Normal Samples
POSITION
SCN1A POLYMORPHISM
FREQUENCY
(%)
Mutation
Amino Acid
Change GEFS Normal
Intron 13 IVS1337CrA … 2.4 8.6
Exon 14 c.2522CrG … 2.4 8.6
Intron 15 IVS1554ArG … 36.3 23.6
Exon 15 c.2889TrC … 1.2 .0
Exon 16 c.3199ArG T1067A 29.5 30.8
Exon 26 c.5782CrG R1928G 1.2 1.7
Figure 2 SCN1A mutations. A, Schematic of SCN1A, showing
positions of the three mutations identified in this study. B, Sodium-
channel amino acid alignments, showing alignment of sodium-channel
amino acids surrounding the three SCN1A mutations.
a phenocopy. A third mutation (c.4968CrG), discov-
ered in the Druze family (fig. 1C), changes an amino
acid (I1656M) in the S4 segment of domain IV (fig. 2).
During the mutation screen of SCN1A, several single-
nucleotide polymorphisms (SNPs) were identified (table
2). The R1928G variant was found at low frequency in
both GEFS and control populations. The T1067A var-
iant was common in both populations. The remaining
SNPs identified did not alter the amino acid sequence
of SCN1A (table 2). The 53 patients with GEFS were
also screened for mutations in SCN1B. Two families
had the same mutation—C121W, due to a c.387CrG
mutation in exon 3—as was seen in the family reported
by Wallace et al. (1998). Details will be presented else-
where.
Discussion
The complete genomic structure of SCN1A has been
determined to enable mutation screening in families with
GEFS. This gene shows high homology to SCN2A and
SCN3A, at both the DNA and the protein levels. The
close proximity of all three of these genes to each other
on chromosome 2 indicates likely duplication events
during the evolution of the sodium-channel–gene family.
Inspection of the splice junctions shows that there is close
agreement with consensus splice motifs, for all introns
bounded by GT-AG—except for introns 2 and 23, which
exhibit deviation from the consensus splice pattern and
are bounded by AT-AC terminal dinucleotides. These
rare splice-site variations are conserved in other char-
acterized sodium-channel subunits (e.g., SCN4A,
SCN8A, and the more distantly related SCN5A), indi-
cating their ancient origin. The intron positions also are
highly conserved, with most variation seen in the region
that codes for the cytoplasmic loop between domains I
and II of the gene. Within this region, an alternative
splicing of exon 11 of SCN1A, comparable to the al-
ternative splicing of exon 10B in SCN8A, was found
(Plummer et al. 1998). Cytoplasmic loop 1 varies in both
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length and composition and is the proposed site of func-
tional diversity among different sodium channels (Plum-
mer and Meisler 1999).
Determination of the genomic structure of SCN1A,
which was in progress when the first SCN1Amutations
were reported (Escayg et al. 2000), facilitated the design
of primers for mutation screening of patients with
GEFS. GEFS has been shown to be due to mutations
in two sodium-channel subunits (Wallace et al. 1998;
Escayg et al. 2000). Among the 53 probands with
GEFS, three new SCN1A mutations were identified;
these were in three families of different ethnic back-
grounds and segregated with the GEFS phenotypes.
One of the mutations, I1656M, is similar to those de-
scribed by Escayg et al. (2000), in that it lies within the
S4 segment of the transmembrane domain. The S4 seg-
ment has a role in channel gating and mutations in this
region of SCN1A reduce the rate of inactivation (Ku¨hn
and Greeff 1996). The V1353L mutation is within the
S5 segment of transmembrane domain III, in a highly
conserved region. Mutations in the S5 segments of
SCN4A that cause hyperkalemic periodic paralysis have
been shown also to affect the rate of channel inacti-
vation (Bendahhou et al. 1999). The D188V mutation
lies just outside the S3 segment of transmembrane do-
main I, in another highly conserved region of SCN1A.
This mutation was not detected in 120 control chro-
mosomes and segregates with the affected members of
the family. It is possible that D188V is a rare variant
that is in linkage disequilibrium with the true mutation.
The entire coding region of SCN1A was sequenced, and
no other mutations were found. Further studies will be
necessary to determine the effect that D188V has on
sodium-channel function.
The SCN1A mutations that cause GEFS are in dif-
ferent functional domains of the channel, but they all
may lead to decreased inactivation resulting in a per-
sistent depolarizing sodium current and hyperexcita-
bility. The mutations in the muscle sodium-channel
SCN4A that cause skeletal muscle myotonias and pa-
ralysis are similar in that they are found along the length
of the gene. In general, these mutations disable inacti-
vation of the sodium channel, producing either repeti-
tive action-potential firing (myotonia) or electrical si-
lence (paralysis) (Cannon 2000). Similarly, mutations in
different regions of the cardiac sodium channel SCN5A
lead to repetitive electrical activity in the heart, owing
to altered channel inactivation (Bennett et al. 1995;
Wang et al. 1996). As further sodium-channelmutations
are identified, our understanding of the functionally im-
portant domains of this class of ion channel will
increase.
There are now five families known to have SCN1A
mutations (Escayg et al. 2000; present study) and three
families known to have SCN1B mutations (Wallace et
al. 1998; R.H.W., unpublished data). The genetic het-
erogeneity of GEFS is now well established. The pres-
ent study extends the distribution of SCN1A mutations
to populations of Middle Eastern origin. No SCN1A or
SCN1B mutations were found in 17 isolated cases of
GEFS. Of the 36 familial cases studied, 3 had mu-
tations in SCN1A, and 3 had mutations in SCN1B.
Together, SCN1A and SCN1B account for ∼17% (6/
36) of cases of familial GEFS. Some mutations may
have been missed either because they occur outside the
gene regions screened or because the detection rate of
the fluorescent SSCA screening method is !100%. Even
so, the proportion of GEFS caused by these two so-
dium channels is still likely to be low, indicating that
other genes are involved; obvious candidates include
other neuronal sodium channels and proteins that in-
teract with sodium channels.
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